Radiotherapy combined with ICRF 159 (NSC 129943).
D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D005354:Fibrosarcoma / Q000188:drug therapy / Q000532:radiotherapy; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy / Q000532:radiotherapy; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010879:Piperazines / Q000627:therapeutic use*; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects; D011929:Razoxane / Q000009:adverse effects / Q000627:therapeutic use*; D012509:Sarcoma / Q000188:drug therapy / Q000532:radiotherapy*; D013584:Sarcoma, Synovial / Q000188:drug therapy / Q000532:radiotherapy; D012983:Soft Tissue Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*
D010879:Piperazines; D011838:Radiation-Sensitizing Agents; D011929:Razoxane